Neuronetics largest shareholder pushes for strategic review

Investor Jorey Chernett (≈14.12% holder) demanded an immediate strategic review including a potential sale of the TMS business, arguing a separation could deliver 5–7x current equity value; Neuronetics trades at a $122M market cap and shares are down 47% over six months. Operationally the company reported LTM negative EBITDA of $27.63M and is burning cash, but posted Q4 2025 revenue of $41.8M (2.73% beat) and EPS of -$0.10 (11.11% miss); management named Dan Reuvers CEO and reported a cash-flow-positive quarter. Canaccord cut its price target from $7 to $3 while keeping a Buy rating, underscoring valuation concerns amid activist pressure and potential restructuring.

Analysis

The activist letter is a strategic forcing event that widens the buyer universe: a carve‑out makes the device/IP asset attractive to strategic medtechs and the clinic roll‑up attractive to PE, which typically pay higher multiples for scale and predictable cash flow. A separated device business is more likely to attract acquirers willing to pay for gross margin expansion and recurring service revenue; conversely, clinics will trade on EBITDA multiple expansion only if path to positive free cash flow and centralized ops is credible.

Operationally, the most important second‑order lever is working capital and manufacturing scale: a device buyer can compress COGS and capex intensity by consolidating production or outsourcing, meaning a 200–500bps margin expansion is plausible within 12–24 months post‑transaction. The clinic side faces different dynamics — labor intensity and reimbursement variability create asymmetric downside; PE buyers will focus on margin per site and ability to roll up referrals, which implies the clinic valuation is binary (consolidation or distressed sale) over a 6–18 month window.

Key risks cluster around process failure and execution: a protracted review without a bidder can accelerate cash depletion and force equity raises that dilute activists and long holders, while a quick auction risks fire‑sale pricing to well‑capitalized buyers. Catalysts to watch in the next 30–90 days are formal engagement of advisors, exclusivity letters, and any bridge financing or earn‑outs that would signal a take‑private path; over 6–12 months watch clinic same‑store metrics and device margin trajectory under new management.

Key Decisions for Investors

• Event‑driven long STIM (small sizing: 0.5–1% portfolio) — buy into any post‑letter weakness and hold 3–12 months. Hedge downside with a 3–6 month put or allocate max loss to 30% of position. Base case: 2–3x upside if a disciplined auction or break‑up occurs; tail risk is full dilution or prolonged cash burn.
• Buy a defined‑risk options spread on STIM (6–9 month call debit spread) to capture re‑rating while capping premium paid. Target 3:1+ asymmetric payout if a sale process or activist settlement accelerates; max downside limited to premium (position size 0.25–0.5% portfolio).
• Pair trade (relative value): long STIM / short a public national clinic consolidator (e.g., ACHC) sized to net market exposure — horizon 6–12 months. Rationale: carve‑out re‑rates device IP faster than clinic multiples expand; trim if clinic operational metrics improve or if sale terms reveal significant earn‑outs that keep value with sellers.
• Risk management: set alerts for advisor engagement, material insider selling, and any equity raises. Exit or cut positions if cash runway language worsens materially or if board adopts a long, non‑committal review (>120 days) indicating low probability of near‑term liquidity event.